819 reports of this reaction
2.9% of all OBINUTUZUMAB reports
#8 most reported adverse reaction
INFUSION RELATED REACTION is the #8 most commonly reported adverse reaction for OBINUTUZUMAB, manufactured by Genentech, Inc.. There are 819 FDA adverse event reports linking OBINUTUZUMAB to INFUSION RELATED REACTION. This represents approximately 2.9% of all 28,651 adverse event reports for this drug.
Patients taking OBINUTUZUMAB who experience infusion related reaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFUSION RELATED REACTION is a less commonly reported adverse event for OBINUTUZUMAB, but still significant enough to appear in the safety profile.
In addition to infusion related reaction, the following adverse reactions have been reported for OBINUTUZUMAB:
The following drugs have also been linked to infusion related reaction in FDA adverse event reports:
INFUSION RELATED REACTION has been reported as an adverse event in 819 FDA reports for OBINUTUZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFUSION RELATED REACTION accounts for approximately 2.9% of all adverse event reports for OBINUTUZUMAB, making it a notable side effect.
If you experience infusion related reaction while taking OBINUTUZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.